Aerpio Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc. (ticker: ARPO) was a U.S.-listed biotechnology company that traded on NASDAQ in the United States. The company was incorporated in Delaware in 2007, originally as Zeta Acquisition Corp. II, and later evolved into a clinical-stage biopharmaceutical developer focused on vascular biology and ophthalmology. For investors, the key point is that ARPO reflects the legacy Aerpio entity: the company entered into a merger agreement with Aadi Bioscience in 2021, and the combined company adopted the Aadi name, so Aerpio is best understood as a historical public biotech platform rather than an ongoing standalone operating company. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_AADI_2020.pdf)) Operationally, Aerpio was built around compounds designed to activate Tie2, a pathway it believed could have therapeutic potential in diseases with vascular dysfunction. Its lead candidate was razuprotafib, formerly known as AKB-9778, a small-molecule VE-PTP inhibitor. The company explored this asset across several clinical settings, including non-proliferative diabetic retinopathy, open-angle glaucoma, ocular hypertension, and acute respiratory distress syndrome / COVID-19-related indications. In biotech terms, Aerpio was a classic development-stage company: scientific optionality was the asset, while clinical readouts, regulatory progress, and financing availability were the main value drivers. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_AADI_2020.pdf)) From a competitive standpoint, Aerpio did not have commercialized products or an established revenue-generating franchise. Its positioning depended on the novelty of the Tie2 mechanism, the quality of its clinical data, and the market’s willingness to assign value to partnering or M&A outcomes. That placed it in a highly competitive subset of the U.S. biotech universe, where larger ophthalmology and inflammation-focused players, as well as better-capitalized vascular biology platforms, could outspend smaller companies on development and commercialization. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_AADI_2020.pdf)) Geographically, Aerpio’s base of operations was in Cincinnati, Ohio, and its business footprint was primarily U.S.-centric. The most important recent milestones were the January 2021 workforce realignment, the company’s stated review of strategic alternatives to maximize stockholder value, and the May 2021 merger announcement with Aadi Bioscience. For French-speaking investors in Europe, the name ARPO therefore signals a legacy NASDAQ healthcare story in the United States, with value creation historically tied to clinical execution and corporate transactions rather than to a mature product portfolio. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_AADI_2020.pdf))